CRISPR Therapeutics (CRSP) shares closed at US$53.77 on Friday, with recent returns mixed, including a 2.5% gain over the past day but a weaker pattern over the month and the past 3 months. See our ...
The global prime editing and CRISPR market size was US$ 3,194.2 million in 2021. The global prime editing and CRISPR market is forecast to grow to US$ 17,618.4 million by 2030 by registering a ...
Morning Overview on MSN
New CRISPR leap could transform treatment for genetic diseases
Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...
CRISPR Therapeutics stands at a critical juncture as its gene editing technology transitions from clinical promise to commercial reality. The company, focused on developing transformative gene-based ...
CRISPR-based genome engineering revolutionized the gene-editing field by making experimental workflows considerably easier, faster, and more efficient than previous methods. Still, generating reliable ...
UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...
I warned investors in June 2022 to be wary about adding Crispr Therapeutics stock. My Sell rating has panned out accordingly as CRSP significantly underperformed the S&P 500. Despite that, CRSP ...
Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Plant Breeding and CRISPR Plants - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Plant ...
CORALVILLE, Iowa--(BUSINESS WIRE)--Bolstering its commitment to providing researchers with powerful tools to discover more about biology and advance medicine, global genomics solutions provider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback